drug_type
RELEVANT_DRUG
intervention_type
Biological (CAR T-cell therapy)
drug_description
An autologous CD19-directed CAR T-cell therapy in which a patient’s T cells are engineered ex vivo to express a chimeric antigen receptor targeting CD19, leading to T-cell activation, proliferation, cytokine release, and cytotoxic killing of CD19+ B cells; evaluated in relapsed/refractory CD19+ B-cell non-Hodgkin lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express a chimeric antigen receptor targeting CD19. CAR engagement with CD19 triggers CD3ζ/co-stimulatory signaling, leading to T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated killing of CD19+ malignant (and normal) B cells in an MHC-independent manner.
drug_name
C752
nct_id_drug_ref
NCT06210243